A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Destiny Pharma 27 Nov 2020

Competition for XF-73 moves aside, issue approved

Our previous note discussed Destiny’s acquisition of the Phase 3-ready NTCD M3 product for the...

Read more
RUA Life Sciences 23 Nov 2020

Heart valve progress

RUA have announced an earlier than expected update on the testing of its Elast-Eon-coated...

Read more
Cake Box 23 Nov 2020

Celebrating steady, sensible and sustainable growth

Cake Box’s interim results reconfirmed the company’s resilience in the face of extremely adverse...

Read more
Tatton Asset Management 18 Nov 2020

Solid interims. War chest bolstered. Primed to scale.

Tatton delivered solid interim results for the 6 months period ending 30 September 2020, showing...

Read more
Destiny Pharma 10 Nov 2020

A group transformed

While completing the Phase 2b study of their first product, Destiny have announced the planned...

Read more
Strix Group 04 Nov 2020

Capital Markets Day snap reaction

Yesterday Strix hosted a CMD, which contained a very useful ‘route map’ for investors over the next...

Read more
Gattaca 04 Nov 2020

Sailing masterclass amid stormy seas

The company has posted better than expected FY20 results, with net cash closing July at a robust...

Read more
Ultimate Products 03 Nov 2020

Ultimately, there’s brand value

What could have been a “year of living dangerously” for UPGS was a year of living positively....

Read more
RUA Life Sciences 23 Oct 2020

‘A fully formed medical device manufacturer’

RUA Life Sciences announced its trading update for the six months to 30 September 2020. The global...

Read more

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates